PCNT as a target protein for treatment or diagnosis of brain-nervous system diseases

Abstract

Provided are a pharmaceutical composition for preventing or treating a central nervous system disease including, as an active ingredient, cord blood or cord blood-derived cells expressing or secreting pericentrin (PCNT), a composition or kit for diagnosing a central nervous system disease including an agent for measuring a level of PCNT protein, a method of analyzing information required for diagnosing a central nervous system disease using PCNT protein, and a method of screening a candidate substance for a therapeutic agent to treat a central nervous system disease. By using the composition including cord blood or cord blood-derived cells expressing or secreting PCNT, central nervous system diseases may be efficiently prevented or treated. Furthermore, the PCNT protein may be used as a target for diagnosing a central nervous system disease at an early stage and for developing a therapeutic agent for a central nervous system disease.

The invention claimed is: 
     
       1. A method for treating a subject having central nervous system disease, the method comprising: administering to the subject an effective amount of a composition comprising:
 as an active ingredient, leukocytes in cord blood expressing or secreting the amino acid sequence consisting of SEQ ID NO: 1, and erythropoietin (EPO), 
 wherein an expression level of the amino acid sequence consisting of SEQ ID NO: 1 is reduced in the subject having central nervous system disease before the administering the composition as compared with that of a normal individual. 
 
     
     
       2. The method of  claim 1 , wherein the central nervous system disease is selected from the group consisting of cerebral palsy, brain damage, traumatic brain injury, ischemic brain injury, concussion, cerebral contusion, cerebral apoplexy, cerebral infarction, cerebral hemorrhage, Parkinson's disease, Alzheimer's disease, Huntington's chorea, stroke, dementia, Lou Gehrig's disease, Pick disease, Creutzfeldt-Jakob disease, amyotrophic lateral sclerosis, primary lateral sclerosis, degenerative ataxia, multiple sclerosis, nervous system dysfunction, hypomnesis, epilepsy, encephalitis, prion disease, and neuropathy. 
     
     
       3. The method of  claim 1 , wherein the cord blood is autologous cord blood or allogeneic cord blood.